

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-3. (cancelled)

4. (currently amended) The method of claim [[1]] 5, wherein the pharmaceutical composition is an oral dosage form.

5. (currently amended) ~~The method of claim 1, wherein said A method for~~
treating elevated serum triglycerides comprising administering to a human subject with
elevated serum triglycerides an amount of a pharmaceutical composition comprising a
5-lipoxygenase inhibitor, said amount being sufficient to reduce said elevated serum
triglycerides, wherein said 5-lipoxygenase inhibitor is selected from the group consisting
of an acetohydroxamic acid derivative, a phenyl pyrazoline derivative, a 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone derivative, and a 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethyl propanoic acid derivative.

6. (withdrawn) The method of claim 5, wherein said 5-lipoxygenase inhibitor is an acetohydroxamic acid derivative.

7. (withdrawn) The method of claim 6, wherein said acetohydroxamic acid derivative is N-(3-phenoxybenzyl)acetohydroxamic acid (BW 4AC).

8. (original) The method of claim 5, wherein said 5-lipoxygenase inhibitor is a phenyl pyrazoline derivative.

9. (original) The method of claim 8, wherein said phenyl pyrazoline derivative is 4,5-dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine (BW 755c).

10. (withdrawn) The method of claim 5, wherein said 5-lipoxygenase inhibitor is a 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone derivative.

11. (withdrawn) The method of claim 10, wherein said derivative is 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone (AA861).

12. (withdrawn) The method of claim 5, wherein said 5-lipoxygenase inhibitor is a 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethyl propanoic acid derivative.

13. (withdrawn) The method of claim 12, wherein said derivative is 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethyl propanoic acid (MK886).

14. (currently amended) The method of claim [[1]] 5, wherein said effective amount of said 5-lipoxygenase inhibitor is between 0.1 µg and 500 mg per kilogram of body weight.

15. (original) The method of claim 14, wherein said effective amount of said 5-lipoxygenase inhibitor is between 0.5 mg to 500 mg per kilogram of body weight.

16. (currently amended) The method according to claim [[1]] 5, further comprising administering a second compound selected from the group consisting of anti-diabetic compounds, lipid-lowering medications and anti-hypertensive compounds.

17. (previously amended) The method according to claim 16, wherein the 5-lipoxygenase inhibitor and said second compound are administered concurrently.